Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase 1
Completed
- Conditions
- Malignant Pleural Mesotherioma
- Registration Number
- NCT00251550
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
- Inapplicable for radical operation
- Not received prior systemic chemotherapy
- Performance status: 0-1
Exclusion Criteria
- Having a history of sensitivity to platinum agent, folic acid or vitamin B12
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
- Secondary Outcome Measures
Name Time Method Safety QOL Duration of response Progression free survival Median survival time 1 year survival rate Pulmonary function Plasma concentration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pemetrexed and cisplatin synergy in malignant pleural mesothelioma?
How does the pemetrexed-cisplatin regimen compare to standard-of-care therapies for mesothelioma in clinical trials?
Which biomarkers correlate with response to pemetrexed plus cisplatin in chemo-naive mesothelioma patients?
What adverse events were reported in NCT00251550 and how do they align with platinum-based therapy safety profiles?
Are there alternative antifolate-platinum combinations or competing drugs for mesothelioma treatment post-2006?
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
🇯🇵Tokyo, Japan
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician🇯🇵Tokyo, Japan